Close

Exclusive: Ackman's Pershing Square shakes up fees amid losses

Go back to Exclusive: Ackman's Pershing Square shakes up fees amid losses

Valeant Pharma (VRX) Trades at New Lows Amid Ex-Executive Probe

October 31, 2016 3:59 PM EDT

Valeant Pharma (NYSE: VRX) is trading at fresh 52-week lows following reports ex-CEO, Michael Pearson and ex.-CFO, Howard Schiller, are the focus of criminal probe related potential accounting fraud tied to the company's hidden Philidor Rx Services company.

Shares last traded down 12.4% to $17.83.

... More